Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives:Early-onset Alzheimer disease (EOAD) diagnosis often represents a challenge because of the high frequency of atypical presentations. Our aim was to describe the clinical features, APOE genotype, and its pathologic correlations of neuropathologic confirmed EOAD.
Methods:Retrospective review of clinical data (age at onset, family history, clinical presentation, diagnostic delay, diagnosis) and APOE genotype of patients with neuropathologically confirmed EOAD (<60 years).
Results:Forty cases were selected. Mean age at onset was 54.5 years (range 46–60). The mean disease duration was 11 years with a mean diagnostic delay of 3.1 years. A total of 37.5% had a nonmemory presentation. Behavioral/executive dysfunction was the most prevalent atypical presentation. Incorrect initial clinical diagnoses were common (53%) in patients with atypical presentations, but rare when anterograde amnesia was the presenting symptom (4%). The incorrect initial clinical diagnoses were 2 behavioral variant frontotemporal lobar degeneration, 2 normal pressure hydrocephalus, 1 semantic dementia, 1 primary progressive aphasia, 1 corticobasal degeneration, 1 pseudodementia with depression, and 1 unclassifiable dementia. APOE genotype was ϵ3/ϵ3 in 59%, with no significant differences between typical and atypical presentations. APOE ϵ4 was 3.3 times more frequent in subjects with family history of AD. A total of 97.5% of the cases presented advanced neurofibrillary pathology. A total of 45% of the patients had concomitant Lewy body pathology although localized in most cases and without a significant clinical correlate.
Conclusion:One third of patients with pathologic confirmed EOAD presented with atypical symptoms. Patients with EOAD with nonamnestic presentations often receive incorrect clinical diagnoses.
Footnotes
Study funding: Supported by the Hospital Clinic-Emili Letang postresidency grant (M.B.).
Supplemental data at www.neurology.org
-
- AD
- Alzheimer disease
- CBD
- corticobasal degeneration
- CBS
- corticobasal syndrome
- EOAD
- early-onset Alzheimer disease
- FTLD
- frontotemporal lobar degeneration
- LB
- Lewy body
- LOAD
- late-onset Alzheimer disease
- NPH
- normal pressure hydrocephalus
- NTB/UB/HC
- Neurological Tissue Bank, University of Barcelona–Hospital Clínic
- PCA
- posterior cortical atrophy
- PPA
- primary progressive aphasia
- SemD
- semantic dementia
- Received November 10, 2010.
- Accepted February 10, 2011.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Age-at-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer DiseaseDenis S. Smirnov, Douglas Galasko, Annie Hiniker et al.Neurology, March 15, 2021 -
Views and Reviews
Classification of primary progressive aphasia and its variantsM.L. Gorno-Tempini, A.E. Hillis, S. Weintraub et al.Neurology, February 16, 2011 -
Article
CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degenerationDaniel Alcolea, Eduard Vilaplana, Marc Suárez-Calvet et al.Neurology, June 07, 2017 -
Article
Classification and pathology of primary progressive aphasiaJennifer M. Harris, Claire Gall, Jennifer C. Thompson et al.Neurology, October 18, 2013